Median Technologies S.A. (ALMDT.PA)
Median Technologies S.A. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Valbonne, PAC, FR. The stock last traded at $4.63, up 10.12% on the session, giving a market capitalisation of $224.9M. Its beta of 0.51 implies it has historically moved less than the broad market.
Headquartered in Valbonne, France, Median Technologies S.A. was established in 2002. This company specializes in developing and commercializing advanced software and platforms designed for medical image analysis. Its reach extends globally, serving markets in France, the United States, Canada, the United Kingdom, China, and beyond. Among its key offerings is iBiops, an innovative, AI-powered software classified as a medical device. This solution comprehensively integrates and optimizes the entire medical imaging workflow. Additionally, Median Technologies provides iSee, a service dedicated to image analysis specifically for clinical trials. Furthermore, the company delivers extensive imaging contract research organization (CRO) services. These encompass a wide range of activities, from study initiation and the management of both image and clinical data, to scientific advisory, independent reviews, image data processing, site support, and final study close-out. Solidifying its commitment to research, Median Technologies maintains a collaborative agreement with the University of California.
Median Technologies S.A. is most often compared with the following Healthcare names: